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We determined the ability of a model nanoparticle (NP) (titanium dioxide, TiO2) to modulate sensitization induced
by a known potent dermal sensitizer (dinitrochlorobenzene) using a variant of the local lymph node assay called
lymph node proliferation assay.
BALB/c mice received sub-cutaneous injections of vehicle (2.5 mM sodium citrate), TiO2 NPs (0.004, 0.04 or 0.4 mg/
ml) or pigment particles (0.04 mg/ml) both stabilized in sodium citrate buffer at the base of each ear (2x50μl),
before receiving dermal applications (on both ears) of 2,4-Dinitrochlorobenzene (DNCB) (2x25μl of 0.1%) or its
vehicle (acetone olive oil – AOO (4:1)) on days 0, 1 and 2. On day 5, the stimulation index (SI) was calculated as a
ratio of 3HTdR incorporation in lymphocytes from DNBC-treated mice and AOO-treated controls. In a second
experiment the EC3-value for DNCB (0 to 0.1%) was assessed in the absence or presence of 0.04 mg/ml TiO2. In a
third experiment, the lymphocyte subpopulations and the cytokine secretion profile were analyzed after TiO2
(0.04 mg/ml) and DNCB (0.1%) treatment.
Injection of NPs in AOO-treated control mice did not have any effect on lymph node (LN) proliferation. DNCB
sensitization resulted in LN proliferation, which was further increased by injection of TiO2 NPs before DNCB
sensitization. The EC3 of DNCB, with prior injection of vehicle control was 0.041%, while injection with TiO2
decreased the EC3 of DNCB to 0.015%. TiO2 NPs pre-treatment did not alter the lymphocyte subpopulations, but
significantly increased the level of IL-4 and decreased IL-10 production in DNCB treated animals.
In conclusion, our study demonstrates that administration of nano-TiO2 increases the dermal sensitization potency
of DNCB, by augmenting a Th2 response, showing the immunomodulatory abilities of NPs.
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Nanoparticles of titanium dioxide (TiO2) are one of the
most abundantly produced and widely utilized nanoma-
terials [1], with applications in sunscreens, cosmetics,
tooth pastes, and food products [2-4]. Other important
industrial applications include water clean-up technol-
ogy, oxygen sensor and antimicrobial coatings and cer-
amics. Titanium nanomaterials have proved their
potentials in the fields of drug and gene delivery [2].
Although considered as an inert material, titanium
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reproduction in any medium, provided the ormicrometric and nanometric particles and debris in the
surrounding body fluids and tissues which can cause
health effects either at the implant site or in distant
organs [5-8]. A variety of newly developed house hold
products (including self-cleaning spray and paint) have
been reported to contain TiO2NPs. According to the Pro-
ject on Emerging Nanotechnologies (Woodrow Wilson
International Center for Scholars), as of 10th of March
2011, 1317 consumer products containing NPs are
already on the market and if the same trend persists this
number is expected to reach 3400 by the year 2020. TiO2
is the 3rd largest material used in the consumer products.
Effects of NPs on biological systems are unknown or
under debate [9,10]. Nevertheless, the widespread uses
of TiO2 NPs confirm the possibilities of exposure
through ingestion, inhalation and dermal routes. Takenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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particular skin care products) containing TiO2 nanoma-
terials, there is an urgent need for assessing these newly
developed materials for their possible skin sensitizing
potentials as well as for their impact on the skin
sensitization caused by the other chemicals.
Allergic skin sensitization caused by chemicals is a ser-
ious environmental and occupational health hazard. It is
the most frequent manifestation of immunotoxicity in
humans [11]. Literature reports identify more than 3700
chemical as skin sensitizers [12]. Based on positive skin
sensitization tests in animals, it is predicted that in the
near future an increase in the number of chemicals cap-
able of causing contact dermatitis in humans will follow.
Dinitrochlorobenzene (DNCB) is a well-known skin
sensitizer. It is the most used chemical to study contact
hypersensitivity of the skin and the pathogenesis of con-
tact dermatitis [13,14]. Contact dermatitis observed after
DNCB application is a T-cell mediated immune response
[15]. DNCB formed covalent complexes with various
proteins after topical application and act as immunogen
which are taken up by antigen presenting cells (APC),
processed and presented to T cells for activation.
The Local Lymph Node Assay (LLNA) is an OECD
approved protocol to assess dermal sensitizing capacity
of chemicals (OECD guideline no. 429, 2002) [16]. A
modified version of this test, lymph node proliferation
assay (LNPA), has recently been suggested as more ap-
propriate test methodology for the evaluation of NP
induced delayed type hypersensitivity reaction [17,18].
The major advantage of LNPA/LLNA includes the possi-
bility to calculate chemicals relative potency of inducing
dermal sensitization.
The aim of this study was to evaluate the effect of a
prior administration of TiO2 NPs on the dermal
sensitization potential of DNCB. We hypothesized that
TiO2 NPs might act as an adjuvant for a skin sensitizer,
such as DNCB. To our knowledge, this is the first study
to describe the effect of NPs on the dermal sensitization
potential of a well-known chemical sensitizer.
Results
Figure 1 shows the details on the particle characteristics.
Analysis of homogeneous suspensions of the NPs in
2.5 mM sodium citrate by dynamic light scattering
(DLS) showed two populations in the TiO2 samples. Pri-
mary TiO2 particles with a hydrodynamic diameter of
22 nm were detected next to aggregates with a mean
hydrodynamic diameter of 272 nm (Figure 1A). Since
larger particles scatter more photons than small parti-
cles, the intensity weighted distribution is favoured to-
wards larger scatterers. On a number basis, <0.01% of
the particles were agglomerates or aggregates. On a mass
basis, 23.8% of the mass was in agglomerates oraggregates. It shows that a significant number of TiO2
particles exist as primary particles in the suspension.
The ζ potential for TiO2 NPs in 2.5 mM sodium citrate
(−52 mV) was significantly lower as compared to ζ po-
tential in water (−24 mV) (Figure 1A, inset). This low-
ered ζ potential as compared to that observed in water
showed the stabilising effect of sodium citrate on NP
suspensions. TEM analysis revealed a spherical morph-
ology of TiO2 NPs (Figure 1A, inset). For the pigment
TiO2 particles, the DLS analysis also revealed two popu-
lations. A first population has an average diameter of
576 nm, the second population has an average diameter
of 76 nm (Figure 1B). The ζ potential for the pigment
TiO2 particles in 2.5 mM sodium citrate was −22 mV
(Figure 1B, inset). The pigment particles also showed a
rod-like morphology on TEM analysis (Figure 1B, inset).
Figure 2 shows the modulation effect of different doses
of TiO2 NPs on the dermal sensitization with DNCB. In
AOO-treated control mice, a prior injection with TiO2
NP did not influence the SI. When TiO2 NPs were
injected prior to DNCB sensitization, we found an in-
creasing SI, compared to Veh injection prior to DNCB
sensitization. This increased SI was statistically different
using 0.04 and 0.4 mg/ml TiO2 NPs prior to the DNCB
sensitization. Injection of 0.04 mg/ml pigment TiO2 par-
ticles prior to DNCB sensitization was not significantly
different from the group which received an injection
with vehicle prior to DNCB sensitization. However, TiO2
pigment (0.04 mg/ml) injection prior to DNCB
sensitization is statistically different from TiO2 NP
(0.04 mg/ml) injection prior to DNCB sensitization
(p < 0.05, not indicated in figure).
Figure 3 shows the effect of prior TiO2 NP injection on
the EC3 value of DNCB sensitization. Prior injection with
vehicle (Veh), before sensitization with DNCB yielded an
EC3 of 0.041%, while injection with TiO2 NPs (0.04 mg/ml
i.e. 160 μg/kg) before DNCB sensitization led to a shift to
the left and resulted in an EC3 of 0.015%.
In Table 1, the lymphocyte subpopulations of the aur-
icular lymph nodes are presented. Mice subcutaneously
injected with vehicle, followed by 0.1% DNCB
sensitization showed significantly increased levels of
CD3+ (T-cells), CD3+CD4+ (T-helper cells), CD3+CD4+
CD25+ (activated/regulatory T-cells), CD3+CD8+ (T-
cytotoxic cells) and CD19+ (B-cells) in the auricular
lymph nodes. Prior injection of 0.04 mg/ml TiO2 NP be-
fore DNCB sensitization did not change the composition
of the auricular lymph nodes compared to Veh/DNCB
group.
Figure 4 shows the levels of cytokine production in
cultured auricular lymphocytes, in the presence of
ConA. Mice subcutaneously injected with vehicle, fol-
lowed by 0.1% DNCB sensitization showed a significant
increase in the level of IFN-γ (Figure 4A), IL-10
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Figure 1 Physico-chemical characteristics of TiO2 nano (A) and pigment (B) particles in powder and suspension.
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AOO group. When the mice were injected with
0.04 mg/ml TiO2 NPs before DNCB sensitization, the
level of IL-4 (Figure 4D) was also significantly increased,
while the level of IL-10 was decreased, but still signifi-
cantly higher than non-sensitized TiO2 NP treated mice.
The levels of IFN-γ and IL-13 were unchanged by TiO2
NP injection before DNCB sensitization. IL-2 and IL-17
levels were in all groups the same (data not shown).Discussion
Our objective was to evaluate the effects of non-bio-
degradable/biopersistant solid TiO2 NPs on the classical
hypersensitivity reaction to a well-known potent dermal
sensitizer (DNCB). To the best of our knowledge, there
is no information available on the effect of manufactured
NPs on the dermal sensitization potential of chemicals,
in general, and of DNCB in particular. Recently, sensitiz-
ing potentials of biodegradable particles (ethosomes)

























Figure 2 Effect of subcutaneous injections of TiO2 NPs or pigment particles on the skin sensitizing capacity of 0.1% DNCB. Stimulation
Index in lymph node proliferation assay (LNPA). To calculate the SI, all SI’s of the AOO-treated were pooled, since they were not statistically
different from each other. Graph shows mean± SD, n = 5–9, * p< 0.05 and ** p< 0.01.
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tally relevant solid NPs is lacking [19-21]. Here we
demonstrate that TiO2 NPs (0.04 mg/ml) act as an
immune-stimulator on the dermal sensitization capacity
of DNCB. The stimulation of the dermal sensitization
was coupled with a significant change in cytokine release
which corresponds with the induction of a Th2 response.
The experiments confirmed our hypothesis that pre-
treatment with TiO2 NPs modulate sensitization to
DNCB.
There is conflicting evidence about the skin penetra-
tion of nanomaterials [22,23]. However, it has been sug-
gested that NPs could pass through the stratum
corneum of the skin using intercellular channels or hair
follicles and penetrate into deeper skin layers [24,25]. A
thorough search of the available literature indicates that
stratum corneum is an effective barrier against the up-
take of TiO2 NPs in healthy skin. However, various re-












Figure 3 Effect of subcutaneous injections of 0.04 mg/mlTiO2 NPs on
exposed to different doses of DNCB in the presence or absence of TiO2 NP
(⇢), while the EC3 of TiO2/DNCB is 0.015% (!). Graph shows mean± SD, npenetration of TiO2 NPs to the deeper layers of skin/vi-
able skin in case of local damage (sun burns etc) or
when lipid vesicles formulations are involved [19,20,26].
For example, a sub-erythemal dose ultraviolet radiation
exposure (UVB 270 mJ/cm2) in mice has been shown to
allow the penetration of 45 nm quantum dot NPs to
deep dermis [27]. In another study, it has been observed
that 7 nm TiO2 NP exposure with UV irradiation can
lead to increased skin barrier dysfunction and possible
aggravation of contact dermatitis due to increased inva-
sion of Staphylococcus aureus [28]. Interestingly, people
tend to apply more sun screens containing NPs in case
they have damaged skin (sunburns, burns) when the bar-
rier function of skin is already impaired. It has also been
reported that in a skin barrier dysfunction conditions
(mite allergen exposure) intradermal exposure to rutile
TiO2 NPs can lead to aggravation of the atopic skin
lesions [29]. Particles which penetrate normal or





the dose–response curve (SI) of DNCB sensitization. Mice were
pre-treatment (0.04 mg/ml). The EC3 value of Veh/DNCB is 0.041%
= 5-9, *p< 0.05.
Table 1 Lymph node cell subpopulations (x106) per
lymph node
Veh/AOO Veh/DNCB TiO2/AOO TiO2/DNCB
CD3+ 0.66 ± 0.21 2.06 ± 0.56*** 1.16 ± 0.57 2.27 ± 0.59+++
CD3+CD4+ 0.47 ± 0.15 1.47 ± 0.41*** 0.81 ± 0.38 1.56 ± 0.43+++
CD3+CD4+CD25+ 0.04 ± 0.01 0.16 ± 0.05*** 0.06 ± 0.03 0.13 ± 0.02++
CD3+CD8+ 0.18 ± 0.06 0.59 ± 0.15*** 0.34 ± 0.20 0.68 ± 0.19+++
CD19+ 0.12 ± 0.04 0.62 ± 0.22*** 0.23 ± 0.13 0.80 ± 0.30+++
Results are expressed as mean± SD, n = 9-11, ***p< 0.001 Veh/DNCB vs Veh/
AOOand ++p< 0.01, +++p< 0.001 TiO2/DNCB vs. TiO2/AOO.
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subsequently removed via the lymphatic system [9,30].
In view of these considerations, along with the possibil-
ity of exposure in individuals with pathological lesions of
the skin, subcutaneous route becomes a relevant route
to study NP induced effects on dermal sensitization.
TiO2 NP concentrations used in this study are based on
literature reports by us and others describing these as



































































Figure 4 Lymphocyte cytokine production after 0.1% DNCB dermal s
TiO2 or vehicle. On day 5, the auricular lymph nodes are removed and lym
are determined in LNC supernatant. Graphs show mean± SD, n = 10–12, *p[31,32]. Moreover, we did not observe any type of local
injury around the site of injection of NPs.
Our results indicate that TiO2 NPs do not show der-
mal sensitization potential after a single subcutaneous
injection, which is in accordance with findings in litera-
ture [32]. However, subcutaneous presence of TiO2 NPs
significantly increases the skin sensitization potential of
DNCB, which is not the case with subcutaneous pres-
ence of pigment TiO2 particles before dermal
sensitization. It is possible that increased sensitization
after NP exposures is due to binding of the antigen with
the NPs, leading to formation of depot of antigen which
is better recognized by skin APCs. It has been proposed
that ultrafine TiO2 particles (below 30 nm) bind more
ovalbumin per mass unit than fine particles and this
binding may lead to a depot of antigen leading to
increased antigenicity [33]. Moreover, it is a well accepted
fact that professional APCs are more readily stimulated by
the particulate antigens, thus adsorption of antigen per se
can increase the antigenicity [34]. Other possible

































































ensitization or AOO treatment with prior injection of 0.04 mg/ml
phocytes are cultured for 42 h in the presence of ConA. Cytokines
< 0.05, ** p< 0.01 and *** p< 0.001.
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in our experiments as there were no detectable amounts
present in TiO2 NPs utilized in this study.
The results of the present study demonstrate that pre-
exposure to TiO2 NPs does not interfere with the im-
mune system if followed by a sham dermal treatment
(TiO2/Veh). However, when pre-exposure to TiO2 NPs
is followed by DNCB sensitization, a Th2 favoured im-
mune response in regional lymph node cells develops,
with increased IL-4 and decreased IL-10 levels, while
DNCB itself is a known potent Th1 responder [35]. The
apparent IFN-γ secretion confirms the DNCB-induced
Th1 response, even with prior injection of TiO2 NPs.
Nevertheless, TiO2 NPs injection followed by DNCB
sensitization results in significantly increased levels of
IL-4, demonstrating Th2 stimulation. In addition, we
found a decrease in IL-10 secretion. IL-10 is a cytokine
released by several cell types, such as monocytes, acti-
vated T cells, Th2 cells, mast cells and regulatory T cells.
IL-10 is capable of inhibiting pro-inflammatory
responses and is suggested to play a major role in main-
tenance of self-tolerance [36]. We think that sub-
cutaneous exposure to TiO2 in DNCB sensitized mice,
decreased IL-10, and thereby allowing the development
of a Th2 response, independent of the presence of the
Th1 response (levels of IFN-γ are maintained).
Allergic sensitization reactions are the first step against
the “foreign” materials, and are either Th1 or Th2 polar-
ized. It has been shown that particles themselves can act
as modulating agents in skewing the Th responses. Im-
pact of particles on the skewing of Th response is largely
dependent on the chemical nature and characteristics of
the materials. Larsen et al, found that TiO2 NPs pro-
mote allergic sensitization to ovalbumin (IgE and IgG1
levels) and thus primes a Th2 dominated immune re-
sponse [33]. Diesel exhaust can promote both Th1 and
Th2 responses [37,38]. Carbon nanotubes either amplify
Th1 (MWCNT) or Th2 (SWCNT) or both (MWCNT)
responses [39,40]. These studies are done in the models
of respiratory allergy using ovalbumin as sensitizing
agent. However, respiratory allergic responses have
already been shown to be more prone to Th2 skewing
while skin sensitization responses are mostly Th1
dependent [41,42]. It is interesting to note that although
we observe a skewing of immune response towards Th2
we still observe a shift in the potency of DNCB, with al-
most a 3-fold fold decrease in EC3.
Conclusion
In conclusion, we have demonstrated that TiO2 NPs are
effective in modulating the chemical-induced in vivo
dermal sensitization. They probably act as adjuvant to
increase the dermal sensitization capacity of a model
chemical skin sensitizer (DNCB). These findings will behelpful in understanding the NPs induced health effects
and will help in understanding the interactions of NPs
with other sensitizing agents.
Methods
Reagents
2,4-Dinitrochorobenzene was purchased from Sigma-
Aldrich (Bornem, Belgium). Trichloroacetic acid (TCA)
and acetone were obtained from Sigma-Aldrich (Bor-
nem, Belgium). Pentobarbital (Nembutal) was obtained
from Sanofi Santé Animale (CEVA, Brussels, Belgium).
Acetone-olive oil vehicle (AOO) used to dissolve DNCB
was composed of a mixture of 4 volumes of acetone and
1 volume of olive oil (Selection de Almazara, Carbonell,
Madrid, Spain). DNCB concentration is given as percent
(w/v) in AOO. Hanks Balanced Salt solution (HBSS) was
purchased from Invitrogen (Merelbeke, Belgium) and
[Methyl-3 H]-thymidine (3HTdR) was purchased from
ICN Pharmaceuticals (Asse, Belgium).
Nanoparticles
TiO2 NPs (99.9% anatase) of 10–25 nm diameter (15 nm
average diameter) were purchased from Sigma-Aldrich
(Saint Quentin Fallavier, France). These particles were
prepared by sol–gel process and were used without any
post production surface treatments/modifications. Pig-
ment TiO2 was purchased from Cinkarna (Celje, Slo-
venia). Freshly prepared NPs suspensions at desired
concentrations in 2.5 mM sodium Citrate were utilized
to treat the mice.
Physico-chemical Characterization of NPs
Dynamic Light Scattering
DLS analysis of TiO2 pigment and NPs was performed
according to the protocol described by us previously
[43]. Briefly TiO2 pigment and NPs were diluted in
2.5 mM sodium citrate (pH 6.95, ionic strength (I)
515 mM), ultrasonicated and analyzed using Brookhaven
90 Plus instrument (scattering angle: 90°, wavelength:
659 nm, power 15 mW). Correlation functions were ana-
lyzed with the Clementine package (maximum entropy
method) for Igor Pro 6.02A. This resulted in intensity
weighted distribution functions versus decay times. By
converting the decay times with instrument parameters
and physical parameters to hydrodynamic diameters, an
intensity weighted size distribution was obtained. A log-
normal fit was applied on each population resulting in
the average hydrodynamic diameter of the population.
Zeta Potential (ζ ) Measurements
Detailed protocol of ζ potential measurement is pub-
lished elsewhere [43] was measured with a Brookhaven
90Plus/ZetaPlus instrument applying electrophoretic
light scattering. A primary and reference beam (659 nm,
Hussain et al. Particle and Fibre Toxicology 2012, 9:15 Page 7 of 9
http://www.particleandfibretoxicology.com/content/9/1/1535 mW), modulated optics and a dip-in electrode system
were used. The frequency shift of scattered light (relative
to the reference beam) from a charged particle moving
in an electric field is related to the electrophoretic mo-
bility of the particle. The Smoluchowski limit was used
to calculate the zeta potential from the electrophoretic
mobility.
Transmission electron microscopy (TEM)
Suspensions of the TiO2 particles were applied on
formvar-coated cupper mesh grids. After drying over-
night, the NPs were characterized by transmission elec-
tron microscopy (TEM) (JEOL JEM-1200 EX-II, Tokyo,
Japan) at a magnification of 20.000-200.000 x.
Mice
Male BALB/c mice (approximately 20 g, 6 weeks old)
were obtained from Harlan (Horst, The Netherlands).
The mice were housed in a conventional animal house
with 12-hour dark/light cycles. They were housed in
plastic cages with filter tops and received lightly acidified
water and pelleted food (Trouw Nutrition, Gent, Bel-
gium) ad libitum. All experimental procedures were
approved by the local Ethical Committee for Animal
Experiments.
Lymph Node Proliferation Assay (LNPA)
LNPA was performed according to the method
described previously [17,18]. Briefly, one hour prior to
dermal sensitization, on day 0, mice (5–9 animals per
group) were injected sub-cutaneously with NP suspen-
sion or vehicle (Veh) (2.5 mM sodium Citrate) on the
area medial to the implantation of each ear lobe. Subse-
quently, on days 0, 1 and 2, the mice were given dermal
applications (25 μl on each ear) of DNCB in AOO, or
AOO alone. On day 5, the mice were injected intraven-
ously in a tail vein with 250 μl of 20 μCi 3HTdR solution
in HBSS (pH 7.2). Five hours later, the mice were sacri-
ficed by an overdose of Nembutal (90 mg/kg) and aur-
icular lymph nodes were removed, pooled and weighed.
A single cell suspension of lymph node cells (LNC) was
prepared and LNC were washed two times with HBSS.
Subsequently, the LNC were dissolved in 5% TCA and
kept overnight at 4°C. 3HTdR incorporation was evalu-
ated by β-scintillation counting (Beckman LS 5000CE)
and was expressed as disintegrations per minute (dpm).
The stimulation index (SI) was calculated as a ratio of
3HTdR incorporation in lymphocytes from DNBC-
treated mice and AOO-treated controls. A compound
having SI >3 is considered to be a biologically relevant
dermal sensitizer.
a) In a first experiment, mice were subcutaneously
injected with 2x50μl of a 0.004 (low dose), 0.04(medium dose) or 0.4 (high dose) mg/ml NP
suspension, 0.04 (medium dose) mg/ml pigment
particles or vehicle on the area medial to the
implantation of ear lobes. One hour later, the mice
were dermally treated on both ears with (25 μl) of
0.1% DNCB in AOO, or AOO alone and this for 3
consecutive days. On day 5, the LNPA was
performed and the SI calculated.
b) In a second experiment, mice were subcutaneously
injected with 2x50μl of 0.04 (medium dose) mg/ml
NP suspension or vehicle on the area medial to the
implantation of ear lobes. Afterwards, the mice were
treated on each ear with DNCB (0.025, 0.050 or
0.1%) in AOO, or AOO alone, for 3 consecutive
days. On day 5, the LNPA was performed, the SI
calculated, from which the EC3 (effective
concentration yielding a Si of 3) was determined.
Lymph node cell analysis
In a separate group of animals, mice received an NP in-
jection with 0.04 mg/ml TiO2 or vehicle and were after-
wards dermally treated for three consecutive days with
0.1% DNCB sensitization in AOO, or AOO alone, but
on day 5 no 3HTdR was injected and lymph node cells
were isolated. The lymph nodes were kept on ice in
RPMI-1640 (Invitrogen, Merelbeke, Belgium) and cell
suspensions were obtained by pressing the lymph nodes
through a cell strainer (100 μm) (BD Bioscience, Erem-
bodegem, Belgium) and rinsing with 10 ml RPMI-1640.
Cells were counted using a Bürker hemocytometer.
Lymphocytes were washed three times and suspended
(107 cells/ml) in complete tissue culture medium
(RPMI-1640 supplemented with 10% heat-inactivated
fetal bovine serum, 10 mg/ml streptomycin and 100 IU/
ml penicillin).
a) Cell subpopulation analysis:
We stained 5x105 cells with either anti-CD3+ (APC,
T-lymphocytes), anti-CD4+ (APC-Cy7,
Th-lymphocytes), anti-CD8+ (PerCP-Cy5.5,
Tc-lymphocytes) and anti-CD25+ (PE, activated/
regulatory T-lymphocytes) antibodies or with
anti-CD19+ (PE, B-lymphocytes) labelled antibodies,
according to manufacturer’s instructions (BD
Biosciences, Erembodegem, Belgium). All necessary
controls (including isotype controls) were performed
using isotype match control antibodies. Flow
cytometry (FACSArray, BD Biosciences,
Erembodegem, Belgium) was performed using at
least 105 cells.
b) Cytokine analysis:
Cells were seeded into 48-well culture plates at a
density of 106 cells/ml and incubated in complete
RPMI-1640 medium for 42 h containing 2.5 μg/ml
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Belgium). Culture supernatant was collected,
centrifuged (1000 g, 15 minutes at 4°C) and stored at
−80°C till further analysis. Levels of IL-2, IL-4, IL-10,
IL-13, IL-17 and interferon gamma (IFN-γ) were
measured via Cytometric Bead Array and analyzed
with the FCAP Array Software on the FACSArray
(BD Biosciences, Erembodegem, Belgium). Lower
detection limits were 0.2 pg/ml, 0.3 pg/ml, 9.6 pg/ml,
2.4 pg/ml, 0.95 pg/ml and 0.5 pg/ml, respectively.Statistical Analysis
Data are presented as means and SD. All the data were
log transformed for statistical analysis (Graphpad Prism
5.01, Graphpad Software, Inc, San Diego, CA). Data of
Table 1, Figures 2 and 4 were analysed by a one-way
ANOVA followed by Bonferroni post hoc test. In the
post-hoc test, four different comparisons were per-
formed: Veh/AOO vs. Veh/DNCB, Veh/AOO vs. TiO2/
AOO, TiO2/AOO vs. TiO2/DNCB and Veh/DNCB vs.
TiO2/DNCB. Figure 3 was analysed using a two-way
ANOVA followed by a bonferroni post hoc test, compar-
ing Veh vs TiO2 injection prior to DNCB sensitization.
A level of p < 0.05 (two tailed) was considered as
significant.
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